YD Bio Ltd Financials

YD Bio Ltd (YDES) reported $597K in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

YD Bio Ltd (YDES) revenue grew by 16.9% year-over-year, from $510K to $597K in fiscal year 2025.

No, YD Bio Ltd (YDES) reported a net income of -$8.3M in fiscal year 2025, with a net profit margin of -1392.6%.

YD Bio Ltd (YDES) reported diluted earnings per share of $-0.12 for fiscal year 2025. This represents a -500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

YD Bio Ltd (YDES) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, YD Bio Ltd (YDES) had $6.0M in cash and equivalents against $7K in long-term debt.

YD Bio Ltd (YDES) had a gross margin of 28.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

YD Bio Ltd (YDES) had an operating margin of -883.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

YD Bio Ltd (YDES) had a net profit margin of -1392.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

YD Bio Ltd (YDES) generated -$8.0M in free cash flow during fiscal year 2025. This represents a -519.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

YD Bio Ltd (YDES) generated -$6.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

YD Bio Ltd (YDES) had $13.8M in total assets as of fiscal year 2025, including both current and long-term assets.

YD Bio Ltd (YDES) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

YD Bio Ltd (YDES) invested $1.6M in research and development during fiscal year 2025.

YD Bio Ltd (YDES) had 71M shares outstanding as of fiscal year 2025.

YD Bio Ltd (YDES) had a current ratio of 5.88 as of fiscal year 2025, which is generally considered healthy.

YD Bio Ltd (YDES) had a debt-to-equity ratio of -0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

YD Bio Ltd (YDES) had a return on assets of -60.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, YD Bio Ltd (YDES) had $6.0M in cash against an annual operating cash burn of $6.6M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

YD Bio Ltd (YDES) has negative shareholder equity of -$2.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

YD Bio Ltd (YDES) has an Altman Z-Score of 4.24, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

YD Bio Ltd (YDES) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

YD Bio Ltd (YDES) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.